Skip to main content
. 2017 Aug 3;65(11):1780–1790.e1. doi: 10.1093/cid/cix685

Table 2.

Invasive pneumococcal disease incidence after and before vaccine introduction according to serotype and age group in counties using only PCV10 or PCV13

Counties using PCV10 Counties using PCV13
Age group (year) Serotype Pre-PCV7 Incidenceb (2007) Pre-PCV10 Incidenceb (2007–2009) Post-PCV10 Incidenceb (2013–2016) Post-PCV10 vs. Pre-PCV7 Rate Ratio (95% CI)c(1) Post-PCV10 vs. Pre-PCV10 Rate Ratio (95% CI)c(2) Pre-PCV7 Incidenceb (2007) Pre-PCV13 Incidenceb (2007–2009) Post-PCV13 Incidenceb (2013–2016) Post-PCV13 vs. Pre-PCV7 Rate Ratio (95% CI)c(3) Post-PCV13 vs. Pre-PCV13 Rate Ratio (95% CI)c(4) Comparison of Rate Ratios (95% CI)c(4) vs. (2) Comparison of Rate Ratios (95% CI)c(3) vs. (1)
0–4 (N = 16) (N = 41) (N = 26) (N = 22) (N = 51) (N = 24)
All serotypes 15.7
(9.6,25.6)
13.2
(9.7,17.9)
5.7
(3.9,8.4)
0.36
(0.20,0.68)
0.43
(0.27,0.71)
13.6
(9.0,20.6)
10.3
(7.8,13.5)
3.3
(2.2,4.9)
0.24
(0.14,0.43)
0.32
(0.20,0.52)
0.74
(0.37,1.48)
0.67
(0.28,1.56)
PCV7e 11.2
(6.2,20.5)
7.5
(5.0,11.4)
0.7
(0.2,2.0)
0.06
(0.02,0.21)
0.09
(0.03,0.29)
9.3
(5.6,15.5)
6.3
(4.4,8.9)
0.2
(0.0,1.9)
0.02
(0.0,0.21)
0.03
(0.0,0.31)
0.37
(0.03,4.87)
0.38
(0.03,5.25)
1, 5, 7F 1.1
(0.1,8.5)
2.3
(1.1,4.9)
0.0 (0.0,0.8)a 0.00
(0.00,4.26)a
0.00
(0.00,0.41) a
1.2
(0.3,4.9)
1.0
(0.4,2.4)
0.0
(0.0,0.5)a
0.00
(0.0,0.77) a
0.00
(0.00,0.68) a
- -
1 0.0
(0.0,3.7)a
0.0
(0.0,1.2)a
0.0 (0.0,0.8)a - - 0.0
(0.0,2.3)a
0.0
(0.0,0.8)a
0.0
(0.0,0.5)a
- - - -
7F 1.1
(0.1,8.5)
2.3
(1.1,4.9)
0.0 (0.0,0.8)a 0.00
(0.00,4.26)a
0.0
(0.0,0.41) a
1.2
(0.3,4.9)
1.0
(0.4,2.4)
0.0
(0.0,0.5)a
0.00
(0.0,0.77) a
0.00
(0.00,0.68) a
- -
3,6A,19A 2.5
(0.6,10.4)
2.4
(1.1,5.2)
2.0
(1.0,3.9)
0.82
(0.17,3.94)
0.83
(0.31,2.24)
2.5
(0.9,6.8)
2.0
(1.1,3.8)
0.3
(0.1,1.4)
0.13
(0.02,0.79)
0.16
(0.03,0.81)
0.20
(0.03,1.39)
0.16
(0.01,2.03)
3 0.0
(0.0,3.7)a
0.7
(0.2,3.3)
0.5
(0.1,1.9)
Inf
(0.06,Inf)a
0.61
(0.08,4.85)
0.0
(0.0,2.3)a
0.2
(0.0,1.6)
0.3
(0.1,1.4)
Inf
(0.06,Inf)a
1.55
(0.12,19.32)
2.52
(0.08,78)
-
6A 2.0
(0.5,8.3)
1.0
(0.3,3.1)
0.4
(0.1,1.8)
0.22
(0.03,1.54)
0.44
(0.07,2.66)
0.6
(0.1,4.4)
0.2
(0.0,1.4)
0.0
(0.0,0.5)a
0.00
(0.0,4.23)a
0.00
(0.00,13.0)a
- -
19A 0.0
(0.0,3.7)a
0.7
(0.2,2.7)
1.1
(0.5,2.7)
Inf
(0.22,Inf)a
1.67
(0.32,8.80)
1.9
(0.6,5.7)
1.6
(0.8,3.2)
0.0
(0.0,0.5)a
0.00
(0.00,0.38) a
0.00
(0.00,0.39) a
- -
NVT 0.0
(0.0,3.7)a
0.8
(0.2,3.4)
3.0
(1.8,5.2)
Inf
(0.77,Inf)a
3.60
(0.82,15.84)
0.0
(0.0,2.3)a
1.0
(0.4,2.4)
2.7
(1.7,4.3)
Inf
(0.98,Inf)a
2.83
(1.00,8.04)
0.79
(0.14,4.49)
-
6C 0.0
(0.0,3.7)a
0.0
(0.0,1.2)a
0.9
(0.3,2.4)
Inf
(0.20,Inf)a
Inf
(0.61,Inf)a
0.0
(0.0,2.3)a
0.2
(0.0,1.7)
0.0
(0.0,0.5)a
- 0.0
(0.0,13.0)a
- -
5–64 (N = 154) (N = 476) (N = 424) (N = 173) (N = 560) (N = 469)
All serotypes 10.5
(8.9,12.3)
10.8
(9.9,11.8)
7.2
(6.6,7.9)
0.69
(0.57,0.83)
0.67
(0.59,0.76)
8.8
(7.5,10.2)
9.4
(8.6,10.2)
5.4
(5.0,6.0)
0.62
(0.52,0.74)
0.58
(0.51,0.66)
0.87
(0.73,1.04)
0.90
(0.70,1.16)
PCV7e 6.3
(4.9,8.0)
5.2
(4.5,6.0)
0.6
(0.4,0.8)
0.09
(0.06,0.13)
0.11
(0.08,0.16)
4.1
(3.2,5.3)
4.4
(3.9,5.0)
0.4
(0.3,0.6)
0.10
(0.07,0.16)
0.10
(0.07,0.14)
0.92
(0.54,1.58)
1.19
(0.65,2.16)
1,5,7F 1.2
(0.7,2.0)
2.0
(1.6,2.5)
0.6
(0.4,0.8)
0.51
(0.26,0.98)
0.30
(0.20,0.45)
1.5
(1.0,2.2)
1.6
(1.3,1.9)
0.5
(0.4,0.7)
0.35
(0.21,0.57)
0.33
(0.23,0.48)
1.12
(0.65,1.94)
0.68
(0.30,1.58)
1 0.2
(0.1,0.7)
0.2
(0.1,0.4)
0.1
(0.0,0.2)
0.49
(0.12,2.00)
0.44
(0.16,1.22)
0.3
(0.1,0.7)
0.3
(0.2,0.5)
0.1
(0.07,0.2)
0.42
(0.16,1.15)
0.44
(0.20,0.94)
1.00
(0.29,3.57)
0.87
(0.16,4.86)
7F 0.9
(0.5,1.7)
1.7
(1.4,2.2)
0.5
(0.3,0.7)
0.49
(0.24,1.02)
0.27
(0.17,0.42)
1.2
(0.8,1.9)
1.3
(1.0,1.6)
0.4
(0.3,0.5)
0.32
(0.18,0.57)
0.30
(0.20,0.46)
1.12
(0.60,2.08)
0.64
(0.25,1.66)
3,6A,19A 1.4
(0.8,2.4)
1.5
(1.2,2.0)
2.3
(1.9,2.7)
1.64
(0.93,2.89)
1.50
(1.08,2.07)
1.2
(0.8,1.9)
1.2
(1.0,1.6)
0.9
(0.7,1.2)
0.74
(0.45,1.22)
0.75
(0.53,1.05)
0.50
(0.31,0.82)
0.45
(0.21,0.99)
3 0.9
(0.5,1.6)
0.9
(0.6,1.2)
1.2
(1.0,1.6)
1.34
(0.73,2.46)
1.46
(0.95,2.23)
0.6
(0.3,1.2)
0.7
(0.5,0.9)
0.6
(0.4,0.8)
0.91
(0.46,1.77)
0.85
(0.55,1.31)
0.58
(0.32,1.09)
0.68
(0.27,1.68)
6A 0.4
(0.1,1.0)
0.5
(0.3,0.7)
0.1
(0.0,0.2)
0.14
(0.03,0.62)
0.11
(0.03,0.39)
0.3
(0.1,0.8)
0.3
(0.2,0.5)
0.01
(0.0,0.1)
0.04
(0.0,0.32)
0.04
(0.01,0.35)
0.40
(0.03,4.50)
0.27
(0.02,3.46)
19A 0.0
(0.0,0.3)a
0.2
(0.1,0.5)
1.0
(0.8,1.3)
Inf
(3.48,Inf) a
5.14
(2.02,13.13)
0.3
(0.1,0.8)
0.3
(0.2,0.5)
0.3
(0.2,0.5)
1.33
(0.40,4.39)
1.23
(0.62,2.42)
0.24
(0.07,0.83)
-
NVT 1.6
(1.0,2.7)
2.1
(1.7,2.7)
3.8
(3.3,4.3)
2.35
(1.39,3.99)
1.78
(1.37,2.30)
1.9
(1.2,2.8)
2.2
(1.7,2.7)
3.6
(3.2,4.0)
1.92
(1.25,2.94)
1.65
(1.29,2.10)
0.93
(0.64,1.34)
0.82
(0.39,1.69)
6C 0.0
(0.0,0.3)a
0.0
(0.0,0.1)a
0.3
(0.2,0.4)
Inf
(0.87,Inf)a
Inf
(2.62,Inf) a
0.0
(0.0,0.2)a
0.0
(0.0,0.1)a
0.1
(0.0,0.2)
Inf
(0.23,Inf)a
Inf
(0.69,Inf)a
- -
≥65 (N = 174) (N = 583) (N = 719) (N = 137) (N = 499) (N = 726)
All serotypes 47.5
(41.0,55.1)
51.8
(47.8,56.2)
40.8
(37.9,43.9)
0.86
(0.73,1.01)
0.79
(0.71,0.88)
35.7
(30.2,42.2)
42.0
(38.5,45.9)
38.3
(35.6,41.2)
1.07
(0.89,1.29)
0.91
(0.81,1.02)
1.16
(0.99,1.36)
1.25
(0.98,1.60)
PCV7e 26.0
(21.2,31.9)
24.6
(21.8,27.7)
2.8
(2.1,3.7)
0.11
(0.08,0.15)
0.11
(0.08,0.16)
18.2
(13.6,24.3)
21.2
(18.5,24.3)
1.9
(1.4,2.8)
0.11
(0.07,0.17)
0.09
(0.06,0.14)
0.81
(0.50,1.32)
1.00
(0.57,1.76)
1,5,7F 2.4
(1.1,5.1)
3.2
(2.3,4.6)
1.5
(1.0,2.2)
0.62
(0.26,1.47)
0.46
(0.27,0.77)
1.2
(0.3,4.5)
2.0
(1.2,3.2)
1.0
(0.6,1.6)
0.83
(0.21,3.28)
0.51
(0.27,0.99)
1.12
(0.50,2.55)
1.34
(0.26,6.96)
1 0.0
(0.0,1.0)a
0.3
(0.1,0.9)
0.1
(0.0,0.5)
Inf
(0.01,Inf)a
0.22
(0.02,2.19)
0.0
(0.0,1.0)a
0.1
(0.0,0.9)
0.2
(0.1,0.6)
Inf
(0.18,Inf)a
1.77
(0.20,16.04)
8.23
(0.36,188)
-
7F 2.4
(1.1,5.1)
2.9
(2.0,4.3)
1.4
(0.9,2.1)
0.60
(0.25,1.44)
0.48
(0.28,0.83)
1.2
(0.3,4.3)
1.9
(1.1,3.0)
0.8
(0.5,1.3)
0.66
(0.17,2.60)
0.44
(0.22,0.88)
0.91
(0.38,2.16)
1.11
(0.21,5.91)
3,6A,19A 7.9
(5.4,11.6)
9.9
(8.2,12.0)
10.5
(9.0,12.2)
1.32
(0.88,1.98)
1.06
(0.83,1.34)
6.0
(3.6,9.9)
8.0
(6.4,9.9)
9.1
(7.9,10.6)
1.53
(0.91,2.57)
1.15
(0.88,1.49)
1.09
(0.76,1.56)
1.16
(0.59,2.28)
3 3.4
(1.8,6.3)
4.6
(3.4,6.1)
5.1
(4.1,6.3)
1.50
(0.77,2.95)
1.11
(0.78,1.58)
3.8
(2.1,6.9)
3.7
(2.7,5.1)
7.0
(5.9,8.3)
1.84
(1.00,3.40)
1.86
(1.31,2.66)
1.68
(1.01,2.77)
1.22
(0.50,3.03)
6A 3.6
(2.1,6.2)
3.7
(2.7,5.1)
0.5
(0.3,1.0)
0.15
(0.06,0.35)
0.14
(0.07,0.30)
1.1
(0.4,2.9)
2.2
(1.5,3.3)
0.5
(0.3,1.0)
0.48
(0.14,1.62)
0.23
(0.10,0.52)
1.65
(0.58,4.71)
3.26
(0.75,14.12)
19A 0.9
(0.3,3.1)
1.6
(1.0,2.7)
4.9
(4.0,6.0)
5.2
(1.55,17.46)
3.00
(1.75,5.13)
1.1
(0.3,4.0)
2.0
(1.3,3.1)
1.7
(1.1,2.4)
1.57
(0.40,6.13)
0.84
(0.47,1.52)
0.28
(0.12,0.64)
0.30
(0.04,1.9)
NVT 11.2
(8.0,15.6)
14.1
(12.0,16.5)
26.1
(23.8,28.6)
2.34
(1.64,3.32)
1.85
(1.53,2.23)
10.1
(6.4,15.6)
10.9
(8.8,13.4)
26.2
(24.0,28.6)
2.59
(1.66,4.06)
2.41
(1.91,3.0)
1.30
(0.98,1.72)
1.11
(0.65,1.9)
6C 0.0
(0.0,1.0)a
0.2
(0.0,1.0)
4.6
(3.6,5.7)
Inf
(4.11,Inf) a
22.29
(4.71,105.4)
0.3
(0.0,3.7)
0.5
(0.2,1.3)
1.3
(0.9,2.0)
3.86
(0.34,43.7)
2.74
(0.90,8.30)
0.12
(0.02,0.78)
-
All age
groups
(N = 344) (N = 1100) (N = 1169) (N = 332) (N = 1110) (N = 1219)
All serotypes 17.7
(16.0,19.7)
18.8
(17.7,20.0)
14.4
(13.6,15.3)
0.76
(0.67,0.86) d
0.72
(0.67,0.79) d
13.2
(11.8,14.7)
14.5
(13.6,15.3)
10.8
(10.3,11.5)
0.79
(0.70,0.89) d
0.72
(0.67,0.78) d
1.00
(0.89,1.12)d
1.04
(0.88,1.23)d
PCV7e 10.3
(8.8,12.0)
9.0
(8.3,9.9)
1.0
(0.8,1.3)
0.10
(0.07,0.13) d
0.11
(0.09,0.14) d
6.6
(5.4,8.0)
7.1
(6.4,7.9)
0.7
(0.5,0.9)
0.10
(0.07,0.14) d
0.09
(0.07,0.12) d
0.84
(0.58,1.21)d
1.03
(0.67,1.57)d
1,5,7F 1.4
(0.9,2.2)
2.2
(1.8,2.7)
0.7
(0.6,1.0)
0.52
(0.31,0.88) d
0.33
(0.24,0.45) d
1.5
(1.0,2.2)
1.6
(1.3,1.9)
0.6
(0.4,0.7)
0.39
(0.25,0.62) d
0.36
(0.26,0.49) d
1.08
(0.69,1.69)d
0.74
(0.37,1.49)d
1 0.2
(0.1,0.5)
0.2
(0.1,0.4)
0.1
(0.0,0.2)
0.53
(0.14,2.09)
0.38
(0.15,0.96)
0.2
(0.1,0.5)
0.2
(0.1,0.4)
0.1
(0.08,0.2)
0.56
(0.21,1.44)
0.54
(0.27,1.08)
1.42
(0.45,4.47)
1.04
(0.20,5.37)
7F 1.2
(0.8,2.0)
2.0
(1.6,2.4)
0.6
(0.5,0.8)
0.51
(0.29,0.89) d
0.32
(0.22,0.44) d
1.2
(0.8,1.8)
1.3
(1.1,1.6)
0.4
(0.3,0.6)
0.35
(0.21,0.59) d
0.32
(0.22,0.45) d
1.00
(0.61,1.64)d
0.68
(0.31,1.49)d
3,6A,19A 2.7
(1.9,3.6)
3.2
(2.7,3.7)
4.0
(3.6,4.5)
1.42
(1.00,2.01)d
1.20
(0.99,1.45)d
2.1
(1.5,2.8)
2.3
(2.0,2.7)
2.3
(2.0,2.6)
1.04
(0.74,1.47)d
0.93
(0.76,1.14)d
0.79
(0.59,1.05)d
0.75
(0.45,1.26)d
3 1.4
(0.9,2.1)
1.6
(1.3,1.9)
2.0
(1.7,2.4)
1.41
(0.88,2.28)d
1.23
(0.95,1.61)d
1.1
(0.7,1.7)
1.1
(0.9,1.4)
1.6
(1.4,1.9)
1.42
(0.91,2.22)d
1.39
(1.07,1.81) d
1.15
(0.79,1.68)d
1.04
(0.55,1.99)d
6A 1.1
(0.7,1.7)
1.1
(0.9,1.5)
0.2
(0.1,0.3)
0.15
(0.08,0.30) d
0.15
(0.08,0.26) d
0.5
(0.3,0.9)
0.6
(0.4,0.8)
0.1
(0.0,0.2)
0.19
(0.08,0.48) d
0.16
(0.08,0.33) d
1.10
(0.43,2.80)d
1.29
(0.41,4.07)d
19A 0.2
(0.1,0.9)
0.5
(0.3,0.7)
1.8
(1.6,2.2)
7.74
(1.83,32.8) d
3.49
(2.25,5.42) d
0.5
(0.2,1.0)
0.6
(0.5,0.9)
0.5
(0.4,0.7)
1.06
(0.48,2.34)d
0.83
(0.54,1.27)d
0.24
(0.12,0.45) d
0.14
(0.02,0.81) d
NVT 3.4
(2.5,4.5)
4.4
(3.8,5.0)
8.6
(8.0,9.3)
2.36
(1.77,3.15) d
1.84
(1.59,2.13) d
3.0
(2.2,4.2)
3.4
(2.9,4.0)
7.3
(6.8,7.8)
2.30
(1.64,3.22) d
2.05
(1.71,2.45) d
1.11
(0.88,1.40)d
0.98
(0.63,1.50)d
6C 0.0
(0.0,0.2)*
0.05
(0.0,0.2)
1.2
(1.0,1.5)
Inf
(5.94,Inf)*
24.08
(5.04,115) d
0.1
(0.0,1.0)
0.1
(0.0,0.2)
0.3
(0.2,0.4)
4.48
(0.38,52.8)d
2.79
(0.98,7.98)d
0.12
(0.02,0.67) d
-

Comments: 1) In order to make the final results more clear we have decided to present age adjusted rate ratios also within vaccine group (PCV10, PCV13). 2) The estimates for serotype 1 are not age adjusted due to model fitting issues caused by the fact that there were no cases in the age group 0–4. 3) Serotype 6C has now been added to the table. 4) A new column has been added to the end of the table comparing the rate ratios of the two county groups having the year 2007 as baseline.

aThese calculations were made by using an exact method on the observed data.

bIncidence per 100000 population in year (95% Confidence Interval)

cSignificant changes in rate ratios in bold

dAge adjusted ratios

eSerotypes included are: 4, 6B, 9V, 14, 18C, 19F, 23F